No Drug

PreclinicalSmall molecule

Daiichi Sankyo

No Drug is one of 88 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerActive, not recruiting

Multiple SclerosisActive, not recruiting

Triple-Negative Breast CancerPreclinical

Active, not recruiting

Multiple SclerosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

145 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

1 2

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 3

Zyrtec

KKenvue Brands

Phase 3

1 4

Vumerity

Biogen

Phase 3

4 5

Clemastine Fumarate

Novartis

Phase 3

2 6

Mayzent

Novartis

Phase 3

1 7

Antihistamine

Arrowhead Pharmaceuticals

Phase 3

2 8

Recombinant Zoster Vaccine

MMAXVAX Biotechnology Limited Liability Company

Phase 3

1 9

MRI Contrast-Enhancing Agents

Sanofi

Phase 3

3 10

Tolebrutinib

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Not yet recruiting

Multiple Sclerosis

NCT07149662

Clinical

Trials by Indication[1]

Triple-Negative Breast Cancer1 trial

Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo··NCT07092254·760 enrolled

Multiple Sclerosis1 trial

Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy

Not yet recruiting·RRegion Stockholm··NCT07149662·111 enrolled

Chronic Kidney Disease1 trial

Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease

Unknown status·RRamathibodi Hospital·Phase 2·NCT01364688·80 enrolled

Preeclampsia1 trial

PP13 and Doppler Study to Predict Preeclampsia

Unknown status·—·Phase 2/3·NCT00928213·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for No Drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — No Drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for No Drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daiichi Sankyo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Daiichi Sankyo

No Drug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Triple-Negative Breast Cancer1 trial

Multiple Sclerosis1 trial

Chronic Kidney Disease1 trial

Preeclampsia1 trial

References

Drug Info

Quick Facts

Related News